Poster presented at ESMO 2019 by Transgene
Posters on Immunoscore® in Colon Cancer
Poster presented at ASCO20 Virtual Scientific meeting#ASCO20Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients Abstract 4105
Poster presented at ESMO GI 2019 Significant differences in outcome between Immunoscore categories in stage I colon cancer patients
Poster presented at ASCO 2019Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).
Poster presented at Gastrointestinal Cancers Symposium 2019Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided
Poster presented at ESMO IO 2018MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies
Poster presented at ESMO ASIA 2018UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery
Poster presented at ESMO ASIA 2018Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment
Poster presented at ASCO GI 2018Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)
Poster presented at ASCO 2017Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]
Poster presented at SITC 2016Immunoscore® analytical performance
Poster presented at Gastro Intestinal Symposium #GI20Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study
Poster presented at AACR 2018Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay
Poster presented at AACR 2017A new standardized CD8 and PD-L1 dual assay
Poster presented at SITC 2017Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification
Posters on Immunogram
Poster presented at SITC 2019Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture.
Poster presented at SITC 2019Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.
Poster presented at SITC 2019Unveilling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay.
Poster presented at AACR 2019Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept
Posters on LTX-315, a first in class oncolytic peptide, presented by Lytix biopharma involving Immunosign®
Posters on IMMUNOSCORE®CR TL
Poster presented at SITC 2019Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
Poster presented at ESMO 2019High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
Posters on Brightplex®
Poster presented at AACR 2019Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment
Poster presented at the CRI-CIMT-EATI-AACR 2018 T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
Poster presented at SITC 2018 Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
Poster presented at NSH 2017A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections